regulatory
confidence high
sentiment positive
materiality 0.70
Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19
BIOXYTRAN, INC
- FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.
- ProLectin-M is Bioxytran's first program to enter the clinic; it aims to showcase broad-spectrum antiviral potential.
- Prior phase 2 trial showed 100% PCR-negative by day 7 and 88% by day 3; no viral rebounds.
- Company preparing for Phase 3 to seek regulatory approval of ProLectin-M.